## CHD: Church & Dwight Company, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -0.6% below STRENGTH zone (3.0-6.0%); PEG 1.88 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. How Is Church & Dwight's Stock Performance Compared to Other Consumer Staples Stocks?**
- Source: inkl | 20251209T090759 | Neutral | Relevance: 98%
- Church & Dwight (CHD) stock has underperformed significantly compared to the broader Consumer Staples Select Sector SPDR Fund (XLP) over the past three months, year-to-date, and the last 52 weeks. Despite a post-Q3 earnings surge due to better-than-expected results, the stock reflects a bearish trend, trading below its moving averages. Analysts, however, rate CHD as a "Moderate Buy" with a substantial upside potential.

**2. Church & Dwight offloads VitaFusion and L’il Critters to focus on ‘power brands’**
- Source: Cosmetics Business | 20251210T114914 | Neutral | Relevance: 98%
-  Church & Dwight has sold its vitamin brands VitaFusion and L’il Critters to Piping Rock Health Products following a strategic review. This divestiture is part of Church & Dwight's strategy to streamline its portfolio and focus on its remaining "power brands." The deal includes trademarks, licenses, and manufacturing facilities, and is expected to be completed by year-end, resulting in a one-off impairment charge of $40m-$45m.

**3. Church & Dwight to Sell VitaFusion and L’il Critters Brands**
- Source: New Jersey Business Magazine | 20251210T200808 | Somewhat-Bullish | Relevance: 98%
- Church & Dwight Co., Inc. has announced a definitive agreement to sell its VitaFusion and L’il Critters brands to Piping Rock Health Products, Inc. This transaction, which includes manufacturing and distribution facilities, is expected to close by the end of 2025. The sale aims to strengthen Church & Dwight's portfolio and focus on its remaining power brands, while incurring a one-time after-tax charge of $40 million to $45 million.

**4. Church & Dwight to sell VitaFusion and L’il Critters brands to Piping Rock**
- Source: Investing.com Nigeria | 20251209T230924 | Somewhat-Bullish | Relevance: 98%
-  Church & Dwight Co., Inc. (NYSE:CHD) has announced a definitive agreement to sell its VitaFusion and L’il Critters vitamin brands to Piping Rock Health Products, Inc. This strategic move, expected to close by the end of 2025, follows a review of the company's vitamin business, which represents less than 5% of its anticipated 2025 net sales. Church & Dwight anticipates incurring a one-time after-tax charge of $40 million to $45 million in Q4 2025 due to this transaction.

**5. RBC Trims Price Target on Church & Dwight to $100 From $102, Keeps Buy Rating**
- Source: marketscreener.com | 20251210T125126 | Neutral | Relevance: 98%
-  RBC has lowered its price target for Church & Dwight Co., Inc. (CHD) to $100 from $102, while maintaining a "Buy" rating on the stock. This adjustment comes amidst other analyst actions, including Church & Dwight's recent announcement to sell its VitaFusion and L'il Critters brands. The company also recently provided earnings guidance for Q4 and the full year 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Deutsche Bank | $100 | $102 | -2% |
| 2025-12-04 | Argus Research | $102 | $110 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Deutsche Bank | main | Buy |
| 2025-12-04 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 18 ($0.04M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 13.0% (-2.1%)
- Blackrock Inc.: 9.3% (-1.1%)
- State Street Corpora: 5.7% (+2.4%)
- JPMORGAN CHASE & CO: 5.1% (+105.9%)
- Capital Internationa: 4.0% (+0.5%)

### Key Risks

1. Long-term trend broken: trading 12.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.88 elevated, pricing in significant growth expectations. Forward P/E 22.3x stretched relative to 7% growth. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.4B |
| Beta | 0.45 |
| 52W Range | $81.33 - $116.46 |
| Short Interest | 4.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.88 |
| Forward P/E | 22.3 |
| Current P/E | 23.9 |
| YoY Growth | 7.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 3.5pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Below SMA200 (0.88x), long-term trend not supportive. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.55% (CS: 31) | Neutral |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.880x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.57
- **Stop Loss:** $80.21 (4.0% risk)
- **Target:** $86.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 410
- **Position Value:** $34,263.70
- **Portfolio %:** 34.26%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-30 (Est: $0.84)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.74 | $0.81 | +9.9% |
| 2025Q2 | $0.86 | $0.94 | +9.5% |
| 2025Q1 | $0.90 | $0.91 | +1.4% |
| 2024Q4 | $0.77 | $0.77 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*